This article is an erratum on:
Cannabinoid Receptor 2 Signalling Bias Elicited by 2,4,6-Trisubstituted 1,3,5-Triazines
Frontiers Production OfficeAn Erratum on
Cannabinoid Receptor 2 Signalling Bias Elicited by 2,4,6-Trisubstituted 1,3,5-Triazines
by Oyagawa, C. R. M., de la Harpe, S. M., Saroz, Y., Glass, M., Vernall, A. J., and Grimsey, N. L. (2018). Front. Pharmacol. 9:1202. doi: 10.3389/fphar.2018.01202
Due to a production error, 24 references with more than six authors were listed in the Reference list without “et al.” The references affected are Bouaboula et al. (1993, 1996); Felder et al. (1995); Galiegue et al. (1995); Favata et al. (1998); Portier et al. (1999); Kilts et al. (2002); Karsak et al. (2005); Wright et al. (2005); Ofek et al. (2006); Jiang et al. (2007); Valant et al. (2008); Cencioni et al. (2010); Hurst et al. (2010); Schuehly et al. (2011); van der Stelt et al. (2011); Kleyer et al. (2012); Odan et al. (2012); Shonberg et al. (2013); Brailoiu et al. (2014); Herenbrink et al. (2016); Finlay et al. (2017); Soethoudt et al. (2017) and Yrjölä et al. (2015).
The publisher apologizes for this mistake. The original version of this article has been updated.
References
Bouaboula, M., Poinot-Chazel, C., Marchand, J., Canat, X., Bourrie, B., Rinaldi-Carmona, M., et al. (1996). Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. Eur. J. Biochem. 237, 704–711. doi: 10.1111/j.1432-1033.1996.0704p.x
Bouaboula, M., Rinaldi, M., Carayon, P., Carillon, C., Delpech, B., Shire, D., et al. (1993). Cannabinoid-receptor expression in human leukocytes. Eur. J. Biochem. 214, 173–180. doi: 10.1111/j.1432-1033.1993.tb17910.x
Brailoiu, G. C., Deliu, E., Marcu, J., Hoffman, N. E., Console-Bram, L., Zhao, P., et al. (2014). Differential activation of intracellular versus plasmalemmal CB2 cannabinoid receptors. Biochemistry 53, 4990–4999. doi: 10.1021/bi500632a
Cencioni, M. T., Chiurchiu, V., Catanzaro, G., Borsellino, G., Bernardi, G., Battistini, L., et al. (2010). Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors. PLoS ONE 5:e8688. doi: 10.1371/journal.pone.0008688
Favata, M. F., Horiuchi, K. Y., Manos, E. J., Daulerio, A. J., Stradley, D. A., Feeser, W. S., et al. (1998). Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem. 273, 18623–18632. doi: 10.1074/jbc.273.29.18623
Felder, C. C., Joyce, K. E., Briley, E. M., Mansouri, J., Mackie, K., Blond, O., et al. (1995). Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol. Pharmacol. 48, 443–450.
Finlay, D. B., Cawston, E. E., Grimsey, N. L., Hunter, M. R., Korde, A., Vemuri, V. K., et al. (2017). Gas signalling of the CB1 receptor and the influence of receptor number. Br. J. Pharmacol. 174, 2545–2562. doi: 10.1111/bph.13866
Galiegue, S., Mary, S., Marchand, J., Dussossoy, D., Carriere, D., Carayon, P., et al. (1995). Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem. 232, 54–61.
Herenbrink, C. K., Sykes, D. A., Donthamsetti, P., Canals, M., Coudrat, T., Shonberg, J., et al. (2016). The role of kinetic context in apparent biased agonism at GPCRs. Nat. Commun. 7:10842. doi: 10.1038/ncomms10842
Hurst, D. P., Grossfield, A., Lynch, D. L., Feller, S., Romo, T. D., Gawrisch, K., et al. (2010). A lipid pathway for ligand binding is necessary for a cannabinoid G protein-coupled receptor. J. Biol. Chem. 285, 17954–17964. doi: 10.1074/jbc.M109.041590
Jiang, L. I., Collins, J., Davis, R., Lin, K.-M., DeCamp, D., Roach, T., et al. (2007). Use of a cAMP BRET sensor to characterize a novel regulation of cAMP by the sphingosine 1-Phosphate/G(13) pathway. J. Biol. Chem. 282, 10576–10584. doi: 10.1074/jbc.M609695200
Karsak, M., Cohen-Solal, M., Freudenberg, J., Ostertag, A., Morieux, C., Kornak, U., et al. (2005). Cannabinoid receptor type 2 gene is associated with human osteoporosis. Hum. Mol. Genet. 14, 3389–3396. doi: 10.1093/hmg/ddi370
Kilts, J. D., Connery, H. S., Arrington, E. G., Lewis, M. M., Lawler, C. P., Oxford, G. S., et al. (2002). Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs. J. Pharmacol. Exp. Ther. 301, 1179–1189. doi: 10.1124/jpet.301.3.1179
Kleyer, J., Nicolussi, S., Taylor, P., Simonelli, D., Furger, E., Anderle, P., et al. (2012). Cannabinoid receptor trafficking in peripheral cells is dynamically regulated by a binary biochemical switch. Biochem. Pharmacol. 83, 1393–1412. doi: 10.1016/j.bcp.2012.02.014
Odan, M., Ishizuka, N., Hiramatsu, Y., Inagaki, M., Hashizume, H., Fujii, Y., et al. (2012). Discovery of S-777469: an orally available CB2 agonist as an antipruritic agent. Bioorg. Med. Chem. Lett. 22, 2803–2806. doi: 10.1016/j.bmcl.2012.02.072
Ofek, O., Karsak, M., Leclerc, N., Fogel, M., Frenkel, B., Wright, K., et al. (2006). Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc. Natl. Acad. Sci. U.S.A. 103, 696–701. doi: 10.1073/pnas.0504187103
Portier, M., Rinaldi-Carmona, M., Pecceu, F., Combes, T., Poinot-Chazel, C., Calandra, B., et al. (1999). SR 144528, an antagonist for the peripheral cannabinoid receptor that behaves as an inverse agonist. J. Pharmacol. Exp. Ther. 288, 582–589.
Schuehly, W., Paredes, J. M., Kleyer, J., Huefner, A., Anavi-Goffer, S., Raduner, S., et al. (2011). Mechanisms of osteoclastogenesis inhibition by a novel class of biphenyl-type cannabinoid CB(2) receptor inverse agonists. Chem. Biol. 18, 1053–1064. doi: 10.1016/j.chembiol.2011.05.012
Shonberg, J., Herenbrink, C. K., López, L., Christopoulos, A., Scammells, P. J., Capuano, B., et al. (2013). A structure–activity analysis of biased agonism at the dopamine D2 receptor. J. Med. Chem. 56, 9199–9221. doi: 10.1021/jm401318w
Soethoudt, M., Grether, U., Fingerle, J., Grim, T. W., Fezza, F., de Petrocellis, L., et al. (2017). Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity. Nat. Commun. 8:13958. doi: 10.1038/ncomms13958
Valant, C., Gregory, K. J., Hall, N. E., Scammells, P. J., Lew, M. J., Sexton, P. M., et al. (2008). A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand. J. Biol. Chem. 283, 29312–29321. doi: 10.1074/jbc.M803801200
van der Stelt, M., Cals, J., Broeders-Josten, S., Cottney, J., van der Doelen, A. A., Hermkens, M., et al. (2011). Discovery and optimization of 1-(4-(Pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives as a novel class of selective cannabinoid CB2 receptor agonists. J. Med. Chem. 54, 7350–7362. doi: 10.1021/jm200916p
Wright, K., Rooney, N., Feeney, M., Tate, J., Robertson, D., Welham, M., et al. (2005). Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology 129, 437–453. doi: 10.1016/j.gastro.2005.05.026
Keywords: cannabinoid receptor 2 (CB2), G protein-coupled receptor, signalling bias, signalling, synthetic cannabinoid, drug design, medicinal chemistry, immune therapeutics
Citation: Frontiers Production Office (2019) Erratum: Cannabinoid Receptor 2 Signalling Bias Elicited by 2,4,6-Trisubstituted 1,3,5-Triazines. Front. Pharmacol. 10:418. doi: 10.3389/fphar.2019.00418
Received: 28 March 2019; Accepted: 03 April 2019;
Published: 05 April 2019.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2019 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Production Office, production.office@frontiersin.org